Tioga Pharmaceuticals’ Asimadoline Demonstrates Positive Results In A Phase 2b Clinical Trial For The Treatment Of Irritable Bowel Syndrome
Jun 1st 2008Drug InformationIrritable-Bowel Syndrome
Tioga Pharmaceuticals, Inc. announced the results of a recent Phase 2b study of its oral kappa opioid receptor agonist, asimadoline, which demonstrated statistically significant results in the treatment of Irritable Bowel Syndrome (IBS).
More: continued here
No Comments »
Leave a Reply
You must be logged in to post a comment.
